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Abstract: Biomarkers are increasingly used to provide decision making data early in phase I by showing Proof of Mecha-
nism or Proof of Concept (PoM/PoC). For antihypertensive agents, the administration of multiple doses (md) to hyperten-
sive patients is assumed to be necessary for an early go/no-go decision. We compared the effects of an Angiotensin II receptor 
antagonist (ARA) on Plasma Renin and blood pressure (BP) following an oral single dose (sd) and once daily md for seven 
days to healthy volunteers and patients with essential hypertension (diastolic BP 95 mmHg to 114 mmHg; systolic BP 130 
mmHg to 200 mmHg). Methods: 5–12 healthy male subjects/dose received 10 mg to 300 mg ARA sd and 50 to 300 mg md 
for 7 days; patients (9–10/dose) received 20 mg–400 mg ARA for 7 days. The studies were designed as randomized, single-
blind, placebo-controlled, group comparison or crossover dose-escalation studies. Plasma Renin and BP were monitored 
up to 24 hours after dosing. Results: Plasma Renin showed a high interindividual variability in both healthy volunteers and 
patients. Healthy subjects showed a dose- and time-related increase in plasma Renin after sd from 40 mg to 300 mg and md 
of 50 mg to 300 mg (p < 0.05 for doses of 200 mg and 300 mg). In patients, increases in plasma Renin 
occurred at 8 hours and beyond starting at sd of 100 mg and md of 50 mg (p < 0.05 for the dose of 400 mg). While healthy 
volunteers showed no relevant decrease in BP, in hypertensive patients a reduction in BP in doses of 100 mg to 400 mg 
occurred (p < 0.05); effects were more pronounced after md compared to sd. Conclusion: Early PoM for an antihypertensive 
agent can be shown by use of laboratory biomarkers following sd to healthy subjects. PoC can be achieved after sd in 
hypertensive patients. Administration of sd to healthy volunteers is sufﬁ  cient for an early go/no-decision.
Introduction
Drug development has faced a change in paradigm in recent years. Due to increasing development costs 
and time (Grabowski et al. 2002; DiMassi, 2002) in combination with a reduced number of drug approvals 
(Frantz and Smith, 2003; The CMR International, 2004), the Factbook, 2004) the pharmaceutical industry 
seeks to reduce attrition rates by providing decision-making data early in phase I and phase IIa (Kuhlmann, 
1999; Colburn, 2000; Grabowski et al. 2002; DiMassi, 2002; Frantz and Smith, 2003). While pharma-
cokinetics appears to be no longer a major cause of failure (Prentis et al. 1988; Frank and Hargreaves, 
2003; Walker, 2004), there are still high failure rates due to lack of safety and efﬁ  cacy especially in late 
stages of development. In addition, after marketing, drug treatment suffers from a high number of poor 
responders even to commonly used drugs and an increasing rate of withdrawals due to adverse events 
(Silber, 2001). Thus, the challenge is to provide reliable data which allow predicting for the efﬁ  cacy or 
the safety of a drug early in clinical development. As clinical endpoints or true surrogates which predict 
for a clinical endpoint can usually not be applied to early short-term phase I or phase IIa studies, a real 
proof of principle can only be achieved in exceptional cases. Therefore, biomarkers are increasingly 
used to assess the potential of a drug for success in later stages of development. 
A biomarker of drug effects should ideally reﬂ  ect a process on the critical path between the pharma-
cological action of the drug and its effect on a disease. The most common deﬁ  nition of a biomarker is 
given by the National Institute of Health Biomarkers Deﬁ  nition Working Group (Biomarkers Deﬁ  nition 
Working Group, 2001). They deﬁ  ne a biomarker as a laboratory measurement or physiological sign in 
association with a physiologic process of putative therapeutic or diagnostic value. A new mechanistic 
classiﬁ  cation of 7 types of biomarkers is proposed by Danhof et al. based on the location of the biomarker 
in the chain of events from underlying subject genotype or phenotype via drug/metabolite plasma Biomarker Insights 2007: 2 82
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concentrations, molecular target occupancy, 
molecular target activation, physiological 
measures, pathological measures/disease processes 
through to clinical scales (Danhof et al. 2005). 
Thus, biomarkers vary with respect to their close-
ness to the intended therapeutic response. Although 
biomarkers are in general not used for regulatory 
purposes and therefore need not to be fully vali-
dated against clinical endpoints, company deci-
sions to proceed or discontinue a project will rely 
on the biomarker results. Thus, the selection of the 
optimal biomarker as well as the duration of treat-
ment and the selection of the study population are 
critical.
Biomarkers may have their greatest beneﬁ  t in 
providing early Proof of Mechanism (PoM) or 
Proof of Concept (PoC) in exploratory drug devel-
opment in man. The terms PoM, PoC and Proof of 
Principle (PoP) are inconsistently used throughout 
the literature. We deﬁ  ne PoM as proof that the 
proposed pharmacological mechanism of a drug is 
valid in man, e.g. a drug binds to a receptor or 
inhibits an enzyme (Kuhlmann and Wensing, 
2006). The differentiation between PoC and PoP 
is less clear, and often both terms are used synon-
ymously. If one tries to differentiate, the term PoC 
could be used as the translation of the pharmaco-
logical effect into a meaningful laboratory or 
clinical biomarker in healthy subjects or patients, 
whereas PoP could be restricted to effects on a 
valid clinical surrogate or at least a candidate 
surrogate in the target population (Kuhlmann and 
Wensing, 2006). 
For antihypertensive agents, especially those 
directly acting on the Renin-Angiotensin-System, 
the activity of vasoconstrictive hormones and the 
drop in blood pressure may serve to show an early 
PoM and PoC, respectively. In healthy volunteers, 
the vasodilative effect of an antihypertensive agent 
is usually counter-regulated by a compensatory 
increase in sympathetic nerve activity or vasocon-
strictive hormones as Renin or Angiotensin. There-
fore, a substantial decrease in blood pressure is 
often not observed at potentially therapeutic doses. 
Even if blood pressure reductions are observed, a 
meaningful dose response curve can usually not 
be established as a further drop in blood pressure 
is often poorly tolerated. However, the activity of 
vasoconstrictive hormones as Renin and Angio-
tensin may be used as a sensitive biomarker for an 
early PoM and the demonstration of a dose-effect 
relationship in healthy volunteers. To observe 
meaningful blood pressure lowering effects and to 
achieve PoC, the administration of multiple doses 
(md) to hypertensive patients is assumed to be 
necessary; however, the duration of treatment is 
unclear.
BAY 10-6734 is an investigational orally active 
dihydropyridine derivate with a selective compet-
itive antagonism at the Angiotensin II AT1 receptor 
subtype developed for the treatment of arterial 
hypertension. Its main active metabolite BAY 10-
6735 is a reversible Angiotensin II AT1 receptor 
antagonist which in-vitro has been shown to be 
more effective than BAY 10-6734 but is poorly 
absorbed from the gastrointestinal tract (Knorr
et al. 1996). Although the administration of BAY 
10-6734 to healthy volunteers is safe and well 
tolerated and the compound shows favorable phar-
macokinetic and pharmacodynamic properties 
(Breithaupt-Grögler et al. 1997), the development 
of the compound was not further pursued for 
internal reasons. We used single dose (sd) and md 
studies of BAY 10-6734 to compare the pharma-
codynamic effects of different doses of an anti-
hypertensive agent in healthy volunteers and 
patients with essential hypertension. The purpose 
of the investigation was to evaluate if decision 
making data can be provided in a phase I setting 
by sd or md studies in healthy volunteers or if 
studies in hypertensive patients are necessary. In 
addition, the safety of the compound in PoM/PoC 
studies in healthy volunteers compared to patients 
was evaluated.
Materials and Methods
Study design
Healthy volunteer studies
The healthy volunteer studies were conducted at 
the study ward of the Institute of Clinical Pharma-
cology of Bayer HealthCare AG in Wuppertal, 
Germany. The study protocols were approved by 
the Ethics Committees of the North Rhine Medical 
Council, Düsseldorf, Germany, and the studies 
were conducted in accordance with the Declaration 
of Helsinki, Good Clinical Practice guidelines and 
German drug law. All subjects gave written 
informed consent to participate in the studies. 
Healthy Caucasian male subjects, aged 18–45 
years, were eligible to participate. Biomarker Insights 2007: 2 83
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The healthy volunteer studies were ﬁ  rst in man 
dose-escalation studies to evaluate the safety, toler-
ability and pharmacokinetics of the compound. 
Thus, no volunteer was allowed to participate in 
more than one dose step. Doses were escalated as 
long as no unacceptable side-effects occurred. As 
both studies had pilot character, no efforts were 
made to complete the groups up to the planned 
sample size if some volunteers did not qualify for 
participation at screening and a minimum number 
of eight subjects on active medication (n = 5 for 
dose steps with a planned sample size of six 
subjects on active treatment) for the evaluation of 
safety, tolerability and blood pressure was included. 
The 10 mg dose was the dose released as ﬁ  rst in 
man dose, thus, a lower number of volunteers was 
included in this dose step. As part of the explor-
atory nature of a ﬁ  rst in man study, the ﬁ  rst dose 
steps were performed with a solution to allow for 
a better dose adjustment as long as the dose to be 
used in later studies were unknown. At higher 
doses, a capsule was used. 
The sd study was performed in a randomized, 
double-blind, placebo-controlled two-fold cross-
over design (12 planned subjects/dose; n = 6 for 
the 10 mg dose). Subjects were randomly allocated 
to receive doses of 10 mg, 20 mg, 40 mg and 80 mg 
as oral solution and 200 mg and 300 mg as capsule. 
The md study was randomized, double-blind, 
placebo-controlled with 8 (50 mg and 100 mg) and 
12 (200 mg and 300 mg) planned subjects/dose. 
For doses of 50 mg and 100 mg, a parallel group 
design was chosen (n = 6 verum/2 placebo), doses 
of 200 mg and 300 mg were administered in a 
crossover design. The higher starting dose and the 
different doses in the md study were selected on 
the basis of the favourable safety and tolerability 
in sd studies in healthy volunteers as well as the 
availability of capsules. All doses were given once 
daily as capsule in the morning for 7 days. 
On the study days (day 1 and 7 of treatment = days 
of ﬁ  rst and last administration of study drug), study 
drugs were administered with 150 ml of water at 8 am 
after 10 hours overnight fast with breakfast being 
allowed 2 hours after drug administration, on the other 
days, study drugs were taken with breakfast. The 
wash-out phase between the crossover steps was at 
least 7 days. A full medical examination was performed 
at follow-up, no more than 7 days after the last study 
dose. Each BAY 10-6734 dose step was initiated when 
the results of the previous dose step were available 
and if there were no unacceptable adverse effects. 
Patient study
The study in hypertensive patients was conducted 
at LAB GmbH Neu-Ulm, Germany. The study 
protocol was approved by the local Ethics Committee 
and the study was performed in accordance with the 
Declaration of Helsinki, Good Clinical Practice 
guidelines and German drug law. All subjects gave 
written informed consent to participate in the 
studies. Male Caucasian patients, aged 35–70 years, 
with established essential hypertension (diastolic 
blood pressure (DBP) between 95 mmHg and 114 
mmHg and systolic blood pressure (SBP) above 130 
mmHg and below or equal to 200 mmHg) were 
eligible to participate. Hypertension was evident for 
at least six months. Patients unresponsive to Angio-
tensin Converting Enzyme inhibitors as well as 
patients with secondary hypertension or clinically 
relevant diseases of other organs (cardiovascular, 
central-nervous system, gastrointestinal and hepatic, 
pulmonary, renal, endocrine) including insulin 
dependent or uncontrolled diabetes were not eligible 
for participation. All laboratory values including 
parameters for renal function had to be normal 
before start of the study.
The study was designed as a randomized, 
double-blind, placebo-controlled, group compar-
ison, dose-escalation study. Again, doses were 
escalated as long as no unacceptable side effects 
occurred. Based on the unknown sensitivity of 
hypertensive patients to the blood pressure 
lowering effect of the compound, a lower starting 
dose was selected in the patient study than in the 
healthy volunteer study. Hypertensive patients 
received 20 mg, 50 mg, 100 mg, 200 mg, 300 mg 
and 400 mg as capsules once daily for 7 days. A 
placebo run-in period of three to six weeks was 
followed by 13–16 days of hospitalization. Two 
days before administration of the study drugs, 
patients could adapt to the study facilities (placebo 
treatment). For safety reasons, the administration 
of the 400 mg dose was preceded by three days of 
treatment with 200 mg. 
Study drug administration, follow-up investiga-
tion and dose escalation procedure were compa-
rable to healthy volunteer studies. 
Safety and tolerability 
Safety and tolerability were monitored at predeﬁ  ned 
intervals by non-leading questioning (occurrence 
and severity of adverse events), laboratory param-
eters and vital signs (SBP, DBP, heart rate and Biomarker Insights 2007: 2 84
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electrocardiogram (ECG)) daily up to 72 hours 
after the last drug administration. 
Biomarkers
DBP was taken as the primary clinical biomarker. 
The vasoconstrictive hormone Renin served as the 
primary laboratory biomarker. In addition, 
measurements of Angiotensin II and Aldosterone 
were performed. Vasoconstrictive hormones were 
determined by commercially available radio-
immuno assays (Dia Sorin: Plasma-Renin Activity; 
Bühlmann Laboratories AG: Angiotensin II; DPC 
Biermann: Aldosterone) at the Institute of Clinical 
Pharmacology, Bayer HealthCare AG, Wuppertal. 
To note, the assay for Renin changed from the 
healthy volunteer studies to the patient studies. 
Thus, Renin is given as Renin activity (RA; µg/l/h) 
in the healthy volunteer studies and Renin concen-
tration (RC; µU/ml) in the patient study, respec-
tively. Blood pressure and vasoconstrictive 
hormones were determined in supine position after 
15 minutes of rest on days 1 and 7 at 2, 4, 6, 8, 12, 
16 and 24 hours after drug intake in the sd healthy 
volunteer study and the md patient study. In the 
md study in healthy volunteers, hormones were 
determined at baseline and at 2, 4, 12 and 24 hours 
after drug administration.
Pharmacokinetics
Plasma samples for the determination of BAY 10-
6734 and BAY 10-6735 were taken in timed inter-
vals on day 1 and 7 up to 72 hours after the last 
dose. Plasma concentrations were determined by 
HPLC with on column focusing and ﬂ  uorescence 
detection at the Institute of Clinical Pharmacology, 
Bayer HealthCare AG, Wuppertal. Pharmacoki-
netic parameters were evaluated using non-
compartmental methods. 
Statistics
All data were tabulated and subjected to a descrip-
tive statistical evaluation. The statistical analysis 
was based on a linear mixed model for the analysis 
of repeated measurement design. The parameter 
of interest was measured repeatedly within each 
treatment at different time points. Beside the 
overall mean, ﬁ  xed effects were assumed for the 
classiﬁ  cation variable “treatment and time.” To 
allow different time courses, the interaction terms 
between treatment and time were added to the 
model. As variance components, the random 
effects due to subject variability and measurement 
errors were considered in the model. Based on 
these models, means for the treatment groups (least 
square means) as well as treatment differences and 
the corresponding p values for testing of no group 
differences were derived. In addition, data of 
different time points were compared to baseline by 
using the student’s t-test. P < 0.05 was used as the 
minimum level of signiﬁ  cance. Statistical evalua-
tion was performed using the SAS software 
package Version 8. 
Results
Study population
Study characteristics including study designs and 
number of subjects enrolled are given in Table 1. 
Healthy volunteers participating in sd and md 
studies were aged 20 to 45 years, their body 
weights ranged from 53 to 110 kg. No signiﬁ  cant 
differences existed between the different treatment 
groups with respect to age and body weight. Based 
on the natural occurrence of hypertensive disease, 
the age range for inclusion of hypertensive patients 
was different from healthy volunteers. Thus, 
patients with hypertension were older than healthy 
subjects and also showed a higher body weight. 
Their age ranged from 36 to 70 years, the body 
weights from 60–108 kg. Again, no signiﬁ  cant 
differences existed between the different treatment 
groups with respect to age and body weight. Due 
to the rigid exclusion criteria, patients with hyper-
tension showed no other signs of relevant organ 
dysfunction and, therefore, no additional differ-
ences to healthy volunteers.
Laboratory biomarkers
In healthy volunteers, there was a wide interindi-
vidual variability in increase in RA in plasma for all 
doses. Overall, time- and dose-related increases in 
mean RA were observed after sd from 10 mg to 300 
mg (Figure 1). Maximum effects in mean RA 
occurred at 4 h after drug administration for doses 
of 10 mg to 20 mg and at 8 h after drug administra-
tion for doses from 40 mg to 300 mg. Higher than 
2 fold elevations compared to baseline were still 
present at 24 hours for doses from 80 mg to 300 mg. 
Statistical analysis showed statistically signiﬁ  cant 
differences within the 200 mg and 300 mg dose Biomarker Insights 2007: 2 85
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groups (p < 0.05). For both doses values at all time 
points were signiﬁ  cantly different from baseline 
(p < 0.05). When maximum values were compared 
to baseline irrespective of the time point they occurred 
(Table 2), slight increases in RA were observed for 
doses of 10 mg to 40 mg (p < 0.05 for the 10 mg 
dose) while a strong and dose-dependent increase 
was observed for doses of 80 mg (p < 0.01; 6.5 fold), 
200 mg (p < 0.01; 14.8 fold) and 300 mg (p < 0.001; 
19 fold). In the md study, baseline values on day 1 
were comparable to the data in the sd study (no 
statistically signiﬁ  cant difference; Table 3). On day 
7, RA before drug administration was signiﬁ  cantly 
higher than on day 1 (Figure 1; p < 0.05 for doses 
of 100 mg, 200 mg, and 300 mg). Maximum 
changes in mean RA occurred at 4 hours after drug 
administration. Higher than 2 fold elevations were 
present at 24 hours for doses equal to or higher than 
100 mg compared to baseline before the ﬁ  rst dose. 
Again, statistical analyses revealed statistically 
signiﬁ  cant differences within the 200 mg and 300 
mg dose groups (p < 0.05) with all time points being 
significantly different from baseline on day 
1 (p < 0.05). If maximum values were compared to 
baseline irrespective of the time point they occurred, 
increases in RA were more pronounced on day 7 
compared to day 1 or sd (Table 3). To note, as no 8 
hour values were taken, the magnitude of increase 
may be underestimated when compared to the sd 
healthy volunteer study. Angiotensin II and Aldo-
sterone levels showed a high variability and, espe-
cially for Aldosterone, a high number of values 
below LLOQ (lower limit of quantiﬁ  cation). Due 
to this variability, no significant changes were 
observed. However, if maximum changes of Angio-
tensin II were compared to baseline irrespective of 
the time point they occurred, a signiﬁ  cant increase 
was observed for all doses except the 100 mg dose 
on day 1 (Table 3). Changes for the 200 mg and 300 
mg dose were in the order of magnitude as observed 
for RA. Measurements of Aldosterone did not result 
in any statistically signiﬁ  cant difference. 
In hypertensive patients, there was a comparable 
intraindividual variability in RC in plasma. Again, 
time- and dose-related increases in mean RC 
occurred after single doses from 100 mg to 400 mg 
Table 1. Study and subject characteristics of studies in healthy volunteers and patients with essential 
hypertension.
Dose Design    Medication  Planned  Enrolled  Age  Weight
     subjects  subjects
      active   active   years  kg
      treatment/  treatment/  mean ± sd  mean ± sd
Healthy volunteers    placebo   placebo
10 mg   SD, CO  Solution  6  5  33.9 ± 5.4       78 ± 9.0
20 mg   SD, CO  Solution  12  12  32.0 ± 5.8      79 ± 12.4
40 mg   SD, CO  Solution  12  12  34.2 ± 5.1  83.5 ± 12.7
80 mg   SD, CO  Solution   12  10  29.8 ± 6.1  71.9 ± 9.6
200 mg  SD, CO  Capsule  12  9  30.4 ± 5.7  76.3 ± 6.4
300 mg  SD, CO  Capsule  12  12  31.8 ± 5.2  75.8 ± 7.8
Healthy volunteers
50 mg   MD, PG  Capsule  6/2  6/2     31 ± 5.7  78.1 ± 14.4
100 mg  MD, PG  Capsule  6/2  6/2  32.3 ± 6.2  81.8 ± 14.2
200 mg  MD, CO  Capsule  12  9  30.4 ± 5.7  76.3 ± 6.4
300 mg  MD, CO  Capsule  12  10  34.2 ± 6.8  76.5 ± 10.0
Hypertensive Patients
20 mg  MD, PG  Capsule  10/2  10/2  56.1 ± 8.4  93.7 ± 13.2
50 mg  MD, PG  Capsule  10/2  10/2  58.0 ± 6.6  89.9 ± 16.7
100 mg  MD, PG  Capsule  10/2  9/2  53.0 ± 7.1  80.5 ± 12.4
200 mg  MD, PG  Capsule  10/2  9/2  51.9 ± 9.9  81.4 ± 9.3
300 mg  MD, PG  Capsule  10/2  10/2  53.9 ± 8.9  82.2 ± 9.8
400 mg  MD, PG  Capsule  10/2  9/2  52.8 ± 9.6  87.0 ± 13.1
SD = single dose; MD = multiple dose; CO = crossover; PG = parallel group.Biomarker Insights 2007: 2 86
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(Figure 2). Maximum effects were observed at 
8–12 h after drug administration. Higher than 2fold 
elevations compared to baseline were still present 
at 24 hours for doses from 100 mg to 400 mg. Due 
to the great interindividual variability, a statistically 
signiﬁ  cant increase was only detected for the 400 
mg dose (p < 0.05), with all time-points being 
signiﬁ  cantly different from baseline (p < 0.05). As 
in healthy volunteers, following md, baseline 
values on day 7 were signiﬁ  cantly higher than on 
day 1 for doses of 50 mg and above (p < 0.05). At 
24 h, higher than 2 fold elevations were present 
Table 2. Baseline values and maximum increase in Renin and Angiotensin following sd administration of BAY 
10-6734 to healthy volunteers.
Dose [mg/day]  Time    Healthy volunteer
   Renin  [µg/l/h]   Angiotensin [ng/l]
       mean ± sd          mean ± sd
10 mg  Baseline  0.36 ± 0.20    16.5 ± 07.0
  Peak day 1  1.10 ± 0.62
*   20.4 ± 9.3
*
20 mg  Baseline  0.55 ± 0.51    15.3 ± 5.3
  Peak day 1  2.89 ± 5.25    23.6 ± 7.7
*
40 mg  Baseline  0.29 ± 0.13      4.1 ± 3.2
  Peak day 1  0.40 ± 0.24       9.7± 3.8
***
80 mg  Baseline  0.50 ± 0.33      6.4 ± 3.3
  Peak day 1  3.26 ± 2.92
**   13.7 ± 4.7
***
200 mg  Baseline  0.51 ± 0.35      8.6 ± 8.3
  Peak day 1  7.55 ± 6.75
**   46.1 ± 43.8
*
300 mg  Baseline  0.47 ± 0.57      8.8 ± 3.9
  Peak day 1  8.96 ± 4.39
***  58.4 ± 32.4
***
*p < 0.05
**p < 0.01
***p < 0.001
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for doses from 100 mg to 400 mg. Again, a statis-
tically signiﬁ  cant difference was only observed for 
the 400 mg dose group (p < 0.05). Thereby, all 
increases at 8 hours after drug administration and 
beyond showed a statistically signiﬁ  cant difference 
form baseline (p < 0.05). If maximum values on 
days 1 and 7 irrespective of the time point they 
occurred were compared to baseline, signiﬁ  cant 
increases were observed for all but the 100 mg dose 
(Table 3). Due to the higher baseline values, the 
magnitude of increase was lower than observed 
for healthy volunteers (maximum change about 
eight fold). Again, Angiotensin II and Aldosterone 
levels showed a high variability and, especially 
for Aldosterone, a high number of values below 
LLOQ. As in healthy volunteers, statistically 
signiﬁ  cant differences for maximum changes of 
Angiotensin II compared to baseline were observed 
for all doses except the 100 mg dose (p < 0.05; 
Table 3). No difference for Aldosterone was 
observed. 
Clinical Biomarkers
In healthy volunteers, a slight decrease in DBP 
occurred only with the 300 mg dose for sd and md 
(statistically not signiﬁ  cant). In contrast, hyperten-
sive patients showed a statistically signiﬁ  cant 
reduction in DBP in doses of 100 mg to 400 mg at 
2 hours and 50 mg to 400 mg at 12 hours after drug 
administration (p < 0.05; Figure 3). No clear dose 
response relationship was observed. Effects
were more pronounced after md compared to sd 
(Figure 3). The mean maximum decrease in DBP 
was –16 mm Hg for the 400 mg dose on day 7 12 
h after dosing. Normalization of DBP was observed 
in some patients on 300 mg and 400 mg after 7 
days of treatment. Screening values (values before 
start of the washout period), baseline values and 
values at the end of treatment for the different doses 
are given in Table 4. Relevant effects were still 
observed 24 hours after the last dose.
Pharmacokinetics/
Pharmacodynamics
The pharmacokinetic parameters of BAY 10-6734 
and BAY 10-6735 following single doses in healthy 
volunteers are given in Table 5. In healthy volun-
teers, dose-dependent increases in plasma concen-
trations for BAY 10-6734 and BAY 10-6735 were 
observed. No differences were observed between 
day 1 and day 7 of multiple dose treatment. Phar-
macokinetics in patients with hypertension did not 
differ from healthy volunteers. Doses of BAY 10-
6734 and AUC (area under the curve) of BAY 
10-6735 signiﬁ  cantly correlated to RA and RC in 
healthy volunteers and patients, respectively 
(Figures 4 and 5). No clear relationship to DBP 
reductions in patients was observed.
Figure 2. Plasma Renin concentrations in patients with essential hypertension at different times 1 (sd) and 7 (md) days after administration 
of various doses of BAY 10-6734.
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Safety
BAY 10-6734 was safe and well tolerated when 
given to healthy volunteers and patients with 
essential hypertension. The adverse event pattern 
was comparable to what is usually observed in 
healthy volunteer studies in phase I and mostly 
comprised adverse events like headache or nausea 
irrespective of active drug or placebo. The only 
drug related adverse events related to the mode of 
action were two orthostatic reactions—one in the 
highest dose in a patient with essential hyperten-
sion which resulted in discontinuation of the study 
drug and one in a healthy volunteer on the 300 mg 
dose, although this event occurred under both 
active drug and placebo. Due to the observed slight 
blood pressure reduction and the orthostatic reac-
tion at the 300 mg dose in healthy volunteers and 
the orthostatic reaction in one patient at the 400 
mg dose, these doses were taken as the maximum 
tolerated dose for healthy volunteers and patients, 
respectively, and no further dose escalation was 
performed.
Discussion
The results of the present studies demonstrate that 
the determination of a laboratory biomarker such as 
Renin allows achieving an early PoM following a 
single dose of an Angiotensin II receptor-antagonist 
in healthy volunteers. Multiple dosing in healthy 
volunteers and single or multiple dosing in patients 
do not add any further information, neither with 
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Figure 3. Diastolic blood pressure reductions in patients with essential hypertension at different times 1 (sd) and 7 (md) days after 
administration of various doses of BAY 10-6734.
Table 4. Diastolic blood pressure (mean +/- SD) in patients with essential hypertension at screening, at baseline 
(mean of three measurements) and 12 and 24 hours after administration of the last dose of BAY 10-6734. 
Dose [mg/day]  Diastolic Blood Pressure in Hypertensive Patients (mm Hg)
  Screening  Baseline  7 days 12 hours  7 days 24 hours
20 mg  98,8 + 9,6  103,3 + 6,7  92,0 + 8.8  97,6 + 6,2
50 mg  97,8 ± 8,5  105,6 ± 5,1    88,6 ± 10,9  94,8 ± 5,3
100 mg  100,4 ± 10,2  104,7 ± 6,7  92,0 ± 7,7  83,6 ± 6,1
200 mg  98,6 ± 9,4      99,7 ± 4,0  88,6 ± 7,9  90,6 ± 6,8
300 mg  98,9 ± 6,9  101,0 ± 5,2  86,6 ± 9,6  93,6 ± 6,8
400 mg  100,7 ± 6,6      103,2 ± 4,3  85,6 ± 7,2  92,2 ± 7,5Biomarker Insights 2007: 2 90
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respect to a go/no-go decision nor with respect to 
dose selection: despite a high interindividual vari-
ability, dose-effect relationships for Renin were 
comparable for healthy volunteers and patients 
pointing at the 300 mg and 400 mg doses to be 
used in phase II and III. Probably due to the 
absence of inﬂ  uence of disease, Renin changes in 
healthy volunteers were even higher than in 
patients and also showed a better dose-response 
relationship. The Renin assay changed from the 
healthy volunteer studies to the patient study and 
Renin activity to Renin concentration. In a study 
in healthy volunteers and diabetic patients, a strong 
correlation between Renin activity and Renin 
concentration was demonstrated for both study 
populations (Valabhji J et al. 2001). Thus, data for 
healthy volunteers and patients in the present study 
should be comparable. 
In contrast to the results for Renin, no relevant 
effects on blood pressure were detectable in healthy 
volunteers following single or multiple dosing in 
the investigated dose range, thus PoC can only be 
achieved in hypertensive patients. Single dosing 
in patients allows an early PoC, as relevant reduc-
tions in blood pressure could be observed but 
multiple dosing in patients for seven days adds 
Figure 4. Relationship between mean Plasma Renin activities and concentrations and doses of BAY 10-6734 in healthy volunteers and 
patients with essential hypertension on day 1 eight hours after dosing.
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Figure 5. Relationship between mean Plasma Renin activities and concentration and AUC of BAY 10-6735 in healthy volunteers and patients 
with essential hypertension day 1 eight hours after dosing.
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certainty about the dose-effect relationship, the 
potency and the duration of action of the compound. 
However, a short treatment period of 7 days does not 
allow the assessment of the maximum effect of the 
compound as it is not clear if steady state in reduction 
of blood pressure was achieved. Thus, the advantage 
of 7 days versus a 1 day study in patients is question-
able. Instead, a longer treatment period in comparison 
to a gold standard might be preferable. 
An alternative approach to achieve early PoM/
PoC is the application of provocation studies in 
healthy volunteers as often applied in the develop-
ment of antiasthmatics (Smith et al. 1985; Wensing 
et al. 1996). The pharmacodynamic properties of 
an Angiotensin II receptor antagonist can also be 
quantitatively characterized by provocation testing 
from the rightward shift of the agonist dose-
response curve after intravenous administration of 
Angiotensin II to healthy volunteers. For BAY 10-
6734, such a study was performed in healthy 
volunteers applying single oral doses of 20 to 300 
mg (Breithaupt-Grögler et al. 1997). In this study, 
BAY 10-6734 showed to be a fast-acting, highly 
potent and orally active Angiotensin II antagonist 
in man. The observed effects were dose dependent 
and clearly suggested doses of 300 mg and 400 mg 
as clinically effective doses which might allow 
maintaining a relevant blood pressure lowering 
effect for 24 hours. These results correspond to the 
ﬁ  ndings of dose escalation studies in healthy volun-
teers. Although provocation studies in general are 
complicated and more time consuming as dose 
escalation studies, they offer additional value for 
an early go/no-go decision as they allow assessing 
effects on blood pressure and duration of action in 
healthy volunteers. 
A different aspect of applying investigational 
drugs to healthy volunteers or patients is the safety 
of study participants. In healthy volunteers, adverse 
events have been shown to be common and to occur 
with a frequency of about 10% (Sibille et al. 1998; 
Lutfullin et al. 2005). However, the majority of 
adverse events are of mild to moderate intensity 
(Sibille et al. 1998; Lutfullin et al. 2005). Pursuing 
Maximum Tolerated Dose concepts (Sibille et al. 
1998) appears to be associated with a somewhat 
higher rate of medically worrying events than 
concentration or biomarker guided approaches 
(Lutfullin et al. 2005). As for desired effects as 
blood pressure reduction, patients are believed to 
be more sensitive for the occurrence of undesired 
effects. In the present studies there was, however, 
no major difference in the quantity and quality of 
Adverse Events in patients and in healthy volun-
teers. One patient had to prematurely stop dosing 
because of an orthostatic hypotension. However, 
there was also one healthy volunteer who also 
showed this adverse event, although under both 
active drug and placebo treatment. Thus, from the 
point of view of safety and tolerability, PoM or 
PoC studies can be performed in healthy volunteers 
or mildly diseased patients without compromising 
the safety of the study participants.
In conclusion, single dosing in healthy volun-
teers is sufﬁ  cient for an early go/no-go decision 
for the Angiotensin-II receptor antagonist by 
providing PoM by use of a laboratory biomarker 
and allows establishing a dose-effect relationship 
predictive for short-term effects in patients. PoC 
can be achieved either with single dosing in 
patients with hypertension or a provocation study 
with Angiotensin II in healthy volunteers. The 
potency of the compound, the duration of action 
and the time to steady state in blood pressure reduc-
tion may only be fully assessed following longer 
treatment periods. 
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